BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20932288)

  • 1. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
    Langer A
    BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
    Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
    Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Auguste P; Barton P; Hyde C; Roberts TE
    Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.
    Cooper KL; Meng Y; Harnan S; Ward SE; Fitzgerald P; Papaioannou D; Wyld L; Ingram C; Wilkinson ID; Lorenz E
    Health Technol Assess; 2011 Jan; 15(4):iii-iv, 1-134. PubMed ID: 21276372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(16):1-167. PubMed ID: 23074467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med; 2010 Mar; 51(3):401-12. PubMed ID: 20150250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.
    Duarte A; Corbett M; Melton H; Harden M; Palmer S; Soares M; Simmonds M
    Health Technol Assess; 2022 Dec; 26(49):1-184. PubMed ID: 36534989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis.
    Auguste P; Barton P; Meads C; Davenport C; Małysiak S; Kowalska M; Zapalska A; Guest P; Martin-Hirsch P; Borowiack E; Khan K; Sundar S; Roberts T
    BJOG; 2014 Mar; 121(4):464-76. PubMed ID: 24299112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.